Seelos says ALS treatment fails in mid-stage study

(Reuters) – Seelos Therapeutics said on Tuesday that its treatment for a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal of a mid-stage trial.

(Reporting by Christy Santhosh; Editing by Savio D’Souza)